"Immunologic Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
| Descriptor ID |
D007155
|
| MeSH Number(s) |
D27.505.696.477
|
| Concept/Terms |
Immunologic Factors- Immunologic Factors
- Immune Factors
- Factors, Immune
- Immunological Factors
- Factors, Immunological
- Factors, Immunologic
|
Below are MeSH descriptors whose meaning is more general than "Immunologic Factors".
Below are MeSH descriptors whose meaning is more specific than "Immunologic Factors".
This graph shows the total number of publications written about "Immunologic Factors" by people in this website by year, and whether "Immunologic Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 1 | 3 |
| 1994 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 3 | 2 | 5 |
| 2006 | 7 | 1 | 8 |
| 2007 | 5 | 2 | 7 |
| 2008 | 5 | 3 | 8 |
| 2009 | 5 | 6 | 11 |
| 2010 | 8 | 0 | 8 |
| 2011 | 4 | 3 | 7 |
| 2012 | 5 | 4 | 9 |
| 2013 | 2 | 0 | 2 |
| 2014 | 5 | 3 | 8 |
| 2015 | 2 | 2 | 4 |
| 2016 | 4 | 3 | 7 |
| 2017 | 1 | 0 | 1 |
| 2018 | 6 | 2 | 8 |
| 2019 | 7 | 4 | 11 |
| 2020 | 3 | 5 | 8 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunologic Factors" by people in Profiles.
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8.
-
TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer. Biomaterials. 2022 11; 290:121831.
-
Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol. 2022 12; 129(6):758-768.e4.
-
Robust tolerogenic dendritic cells via push/pull pairing of toll-like-receptor agonists and immunomodulators reduces EAE. Biomaterials. 2022 07; 286:121571.
-
High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-13.
-
Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers: Let's Not Forget Radiotherapy. JAMA Oncol. 2022 03 01; 8(3):333-334.
-
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep. 2021 Dec 16; 23(12):30.
-
Inevitable Progress-Relying on the Immune System, Not Chance. Clin Cancer Res. 2022 02 01; 28(3):435-437.
-
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. Eur J Cancer. 2021 11; 157:493-510.
-
Prospective Clinical Investigation of the Efficacy of Combination Radiation Therapy With Immune Checkpoint Inhibition. Int J Radiat Oncol Biol Phys. 2021 12 01; 111(5):1165-1175.